Key facts
- This page summarizes Pablo J. Cagnoni's Form 4 filing for Rubius Therapeutics, Inc..
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 31 Jan 2023, 20:51.
Pablo J. Cagnoni - 29 Jan 2023 Form 4 Insider Report for Rubius Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 29 Jan 2023
- Net transaction value
- -$1,745
- SEC form
- 4
- Accepted by SEC
- 31 Jan 2023, 20:51:39 UTC
- Prior SEC filing
- 22 Jun 2022
- Next SEC filing
- 01 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Kamocsay, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pablo J. Cagnoni filed Form 4 for Rubius Therapeutics, Inc. on 31 Jan 2023.
Change
- Previous filing in this sequence was filed on 22 Jun 2022.
- Current net transaction value: -$1,745.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RUBY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +21,250
- Change %
- +60%
- Price
- Shares after
- 56,770
- Date
- 29 Jan 2023
- Ownership
- Direct
- Footnotes
- F1
RUBY
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +25,000
- Change %
- +44%
- Price
- Shares after
- 81,770
- Date
- 31 Jan 2023
- Ownership
- Direct
- Footnotes
- F1
RUBY
transaction
Common Stock
Sale
- Transaction value
- $1,745
- Shares
- -7,240
- Change %
- -8.9%
- Price
- $0.2410*
- Shares after
- 74,530
- Date
- 31 Jan 2023
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RUBY
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -21,250
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 42,500
- Date
- 29 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,250
- Exercise price
- Footnotes
- F1, F4
RUBY
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -25,000
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 75,000
- Date
- 31 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.26, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F4
The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022.
Footnote F5
The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.
SEC remarks
Exhibit List - Exhibit 24 - Power of Attorney